NCT01417091View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

BPS804

Trial Locations (6)

1200

Novartis Investigative Site, Brussels

9000

Novartis Investigative Site, Ghent

33025

Novartis Investigative Site, Miramar

92801

Novartis Investigative Site, Anaheim

97074

Novartis Investigative Site, Würzburg

H3GIA6

Novartis Investigative Site, Montreal

All Listed Sponsors
lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT01417091 - Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta | Biotech Hunter | Biotech Hunter